KL
Keith R Leonard
Director

Keith R Leonard insider trades: Arcutis Biotherapeutics (ARQT) stock buys and sales

Director, Arcutis Biotherapeutics Last trade Mar 2, 2026 109 Form 4 filings
$997K
Sold, last 12 months
1 sale
$0
Bought, last 12 months
0 buys
45
Open-market trades
since 2013
8
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Keith reports to the SEC

and 2 more companies

Open-market buys and sales

45 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 2, 2026ARQT↓ Sell$997K
Aug 3, 2021ISRG↓ Sell$996K
Feb 13, 2020ISRG↓ Sell$927K
Feb 22, 2019SNNA↑ Buy$250K
Aug 31, 2017ISRG↓ Sell$854K
Aug 1, 2017SNNA↑ Buy$251K
May 23, 2016ANAC↓ Sell$897K
Jun 1, 2015KYTH↓ Sell$844K
May 20, 2015KYTH↓ Sell$175K
May 1, 2015KYTH↓ Sell$584K
Apr 30, 2015KYTH↓ Sell$252K
Apr 15, 2015KYTH↓ Sell$137K
Apr 1, 2015KYTH↓ Sell$652K
Mar 16, 2015KYTH↓ Sell$266K
Mar 2, 2015KYTH↓ Sell$435K
Feb 17, 2015KYTH↓ Sell$169K
Feb 2, 2015KYTH↓ Sell$229K
Jan 2, 2015KYTH↓ Sell$216K
Dec 1, 2014KYTH↓ Sell$225K
Nov 3, 2014KYTH↓ Sell$205K
Oct 23, 2014KYTH↓ Sell$67K
Oct 1, 2014KYTH↓ Sell$125K
Sep 2, 2014KYTH↓ Sell$210K
Aug 4, 2014KYTH↓ Sell$64K
Aug 1, 2014KYTH↓ Sell$120K
Jul 2, 2014KYTH↓ Sell$352K
Jun 16, 2014KYTH↓ Sell$64K
Jun 2, 2014KYTH↓ Sell$113K
May 27, 2014KYTH↓ Sell$60K
May 1, 2014KYTH↓ Sell$111K
Apr 1, 2014KYTH↓ Sell$518K
Mar 3, 2014KYTH↓ Sell$640K
Feb 3, 2014KYTH↓ Sell$578K
Jan 2, 2014KYTH↓ Sell$466K
Dec 2, 2013KYTH↓ Sell$476K
Nov 1, 2013KYTH↓ Sell$529K
Oct 1, 2013KYTH↓ Sell$539K
Sep 16, 2013KYTH↓ Sell$96K
Sep 3, 2013KYTH↓ Sell$224K
Aug 1, 2013KYTH↓ Sell$224K
Jul 15, 2013KYTH↓ Sell$39K
Jul 1, 2013KYTH↓ Sell$222K
Jun 17, 2013KYTH↓ Sell$34K
Jun 3, 2013KYTH↓ Sell$142K
May 2, 2013KYTH↓ Sell$161K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ARQT insiders

Open-market trades in the last 12 months

About Keith R Leonard's insider trades

Keith R Leonard is a director at Arcutis Biotherapeutics (ARQT). Since May 2, 2013, Keith has reported 2 open-market purchases worth $501K and 43 sales worth $15.2M on SEC Form 4. In the last 12 months: 1 sale ($997K).

Their filings also include grants and awards (44 filings), option exercises (20 filings), gifts (9 filings), conversions (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.